T
Tomás Pulido
Researcher at National Institutes of Health
Publications - 98
Citations - 7898
Tomás Pulido is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pulmonary hypertension & Macitentan. The author has an hindex of 27, co-authored 87 publications receiving 6973 citations. Previous affiliations of Tomás Pulido include Harvard University & National Autonomous University of Mexico.
Papers
More filters
Journal ArticleDOI
Bosentan therapy for pulmonary arterial hypertension.
Lewis J. Rubin,David B. Badesch,Robyn J. Barst,Nazzareno Galiè,Carol M. Black,Anne Keogh,Tomás Pulido,Adaani E. Frost,Sébastien Roux,Isabelle Leconte,Michael J. Landzberg,Gérald Simonneau +11 more
TL;DR: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.
Journal ArticleDOI
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Tomás Pulido,Igor Adzerikho,Richard N. Channick,Marion Delcroix,Nazzareno Galiè,Hossein Ardeschir Ghofrani,Pavel Jansa,Zhi-Cheng Jing,Franck-Olivier Le Brun,Sanjay Mehta,Camilla Mittelholzer,Loïc Perchenet,B.K.S. Sastry,Olivier Sitbon,Rogério Souza,Adam Torbicki,Xiaofeng Zeng,Lewis J. Rubin,Gérald Simonneau +18 more
TL;DR: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.
Journal ArticleDOI
Risk stratification and medical therapy of pulmonary arterial hypertension
Nazzareno Galiè,Richard N. Channick,Robert P. Frantz,Ekkehard Grünig,Zhi-Cheng Jing,Olga Moiseeva,Ioana R. Preston,Tomás Pulido,Zeenat Safdar,Yuichi Tamura,Vallerie V. McLaughlin +10 more
TL;DR: The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy, and further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments.
Journal ArticleDOI
Pulmonary arterial hypertension: epidemiology and registries
Michael D. McGoon,Raymond L. Benza,Pilar Escribano-Subias,Xin Jiang,Dave P. Miller,Andrew J. Peacock,Joanna Pepke-Zaba,Tomás Pulido,Stuart Rich,Stephan Rosenkranz,Samy Suissa,Marc Humbert +11 more
TL;DR: The basic methodology by which PAH registries have been conducted is described, key insights provided by registries are reviewed, issues related to interpretation and comparison of the results are summarized, and the utility of data to predict survival outcomes is discussed.
Journal ArticleDOI
Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Nazzareno Galiè,Alan L. Hinderliter,Adam Torbicki,Thierry Fourme,Gérald Simonneau,Tomás Pulido,Nilda Espinola-Zavaleta,Guido Rocchi,Alessandra Manes,Robert P. Frantz,Marcin Kurzyna,Sherif F. Nagueh,Robyn J. Barst,Richard N. Channick,Karl Dujardin,Andrew Kronenberg,Isabelle Leconte,Maurizio Rainisio,Lewis J. Rubin +18 more
TL;DR: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.